603 filings
Page 2 of 31
8-K
bfn9rk2 y5
18 May 23
Results of Operations and Financial Condition
6:57am
8-K
gs0f5f8 jy
10 May 23
Other Events
6:25am
8-K
9fjw 2fmza
5 May 23
Other Events
6:56am
8-K
gsr j4g34h4o1m3ox
4 May 23
Protalix BioTherapeutics Reports First Quarter 2023 Financial and Business Results
7:37am
424B5
xyq8z 8jodfuyh
27 Feb 23
Prospectus supplement for primary offering
7:58am
8-K
y8sr2dcrq66u3094h8
27 Feb 23
Entry into a Material Definitive Agreement
6:48am
8-K
4zo012d5fsy2okc05te
27 Feb 23
Protalix BioTherapeutics Reports Fiscal Year 2022 Financial and Business Results
6:36am
8-K
jlth3570w8tr2 xrc5g
24 Feb 23
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry Disease
9:26am
8-K
cinfu
3 Jan 23
Protalix BioTherapeutics Issues 2023 Letter to Stockholders
6:57am
8-K
trievrq5f0opo6tff8
27 Dec 22
Other Events
4:30pm
8-K
9cusoz5o7ccef
21 Dec 22
Protalix BioTherapeutics to Delist its Common Stock from the Tel Aviv Stock Exchange
4:36pm
8-K
5sonniv0 m5j
14 Nov 22
Protalix BioTherapeutics Reports Third Quarter 2022 Financial and Business Results
7:03am
8-K
tly g7x2f
1 Sep 22
Entry into a Material Definitive Agreement
4:31pm